A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine

Exclusion Criteria

• •Individuals with a history of smallpox, monkeypox, or close contact with monkeypox in the past;
• •Individuals who are allergic to any ingredients of eggs, vaccines, or substances used in production processes, or have a history of other severe allergies;
• •Use immunoglobulin and/or any blood products within 3 months prior to administering the trial vaccine, or plan to use them during the trial period;
• •Currently using salicylate drugs or planning long-term use during the trial period;
• •Have used any experimental or unregistered products within one month prior to administering the trial vaccine, or plan to use them during the trial period;
• •Administer inactivated vaccine within 14 days before administering the experimental vaccine or attenuated live vaccine within 30 days before administering the experimental vaccine;
• •Chronic disease patients are in the acute or progressive phase of chronic disease;
• •Long term use of immunosuppressants or other immunomodulatory drugs within 6 months prior to vaccination with the experimental vaccine;
• •Having undergone chemotherapy or radiation therapy or organ and bone marrow transplantation related treatments for cancer or other diseases;
• •Diseases or medical measures that lead to immune dysfunction, such as congenital immunodeficiency, organ and bone marrow transplantation, leukemia, lymphoma, Hodgkin's disease, multiple myeloma or malignant tumors, etc;
• •Moderate or severe acute illness/infection, or febrile illness on the day of vaccination;
• •Individuals with a history of thrombocytopenia or other coagulation disorders may be contraindicated for subcutaneous injection;
• •Suffering from serious cardiovascular disease, serious liver and kidney disease, and diabetes that cannot be controlled by drugs;
• •Previous history of mental or neurological disorders or family history;
• •Currently suffering from various infectious, suppurative, and allergic skin diseases;
• •Women of childbearing age: pregnant or lactating, or with a positive blood pregnancy test;
• •Plan to move before the end of the trial or leave the local area for a long time during the scheduled trial visit;
• •Abnormal blood routine, blood biochemistry, urine routine, electrocardiogram or heart disease related indicators before vaccination (except for minor abnormalities judged by doctors to have no clinical significance);
• •Researchers believe that any situation that may affect the evaluation of the experiment;
• •Active tuberculosis patients;
• •For HIV infected individuals, the plasma HIV-1 RNA level during screening should be ≥ 200 copies/mL, or positive test for hepatitis B, hepatitis C and syphilis;
• •For healthy people and men and women who have sex with each other, hepatitis B, hepatitis C, syphilis and HIV) are positive;
• •Individuals who experience severe allergic reactions after the first dose of vaccination;
• •Serious adverse events that are definitely related to the first dose of vaccination;